Easton Pharmaceuticals, Inc designs, produces, and sells premium health care products. Most of them use the proprietary transdermal gel formulation that the Canadian company has developed. In 2013, Easton Pharma also announced that it has begun breaking into the medical marijuana sector.
The company was founded in 1997 and originally operated as LAM Pharmaceutical Corp. It became Easton Pharmaceuticals, Inc in 2010.
With a market cap pegged at USD 1.26 M, Easton Pharmaceuticals currently trades in the OTC markets as EAPH.
Products of the company are targeted towards various health issues. Most are applied topically but have transdermal effects due to Easton’s unique proprietary delivery system. There is the arthritis- and body-pain reliever Kenestrin Gel, the anti-wrinkle cream Skin Renou HA, the female sexual enhancement gel Viorra, and the motion sickness reliever gel Nauseasol.
In addition, Easton Pharmaceuticals is working on two major products in its pipeline. These are the early-stage cancer drug called XILIVE and the transdermal treatment for Female Sexual Arousal Disorder (FSAD) called Femlife.
For its entry into the marijuana industry, Easton Pharmaceuticals revealed its intention to establish medical marijuana clinics in Canada and the US. It has also started to discuss investment proposals, such as the one with a Michigan-based medical marijuana dispensary.
The company’s biggest move so far on this front is its investment in AMFIL Technologies. AMFIL is the manufacturer of a plant-growing system called the mPact-GROzone Antimicrobial System, whose technologies reduce pathogens and pests inside cannabis grow facilities.
Easton Pharmaceuticals, Inc is led by CEO and President Carla Pepe, CFO John Adams, COO Kent A Deuters, Treasurer Dr. Peter J. Rothbart, and Chief Marketing and Technology Officer Dr. Lilla Albert. Alongside them is Dr. Daniel Bagi as the Senior Executive Physician Consultant.
Yahoo! Finance: EAPH News
Latest Financial News for EAPH
Oppenheimer & Co. Inc. ("Oppenheimer"), a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced the addition of Gary Domoracki as the Boston office Branch Manager and Managing Director of Investments.
Shares of Oppenheimer Holdings Inc. rallied 4.6% in midday trading Friday, after the middle-market investment bank announced a new program to buy back up to 4.2% of its shares outstanding. The company said its board OK'd the program, which allows Oppenheimer to buy up to 530,000 of its Class A shares. The new program supplements the previous repurchase program, which had 98,625 shares available to repurchase remaining. Oppenheimer had 12.6 million Class A shares outstanding as of May 1. The announcement comes two months after a group representing eight of the U.S.'s largest banks said its members would suspend share buybacks to preserve capital amid the COVID-19 pandemic. Oppenheimer's stock has lost 29.6% over the past three months, while the SPDR Financial Select Sector ETF has dropped 33.0% and the S&P 500 has declined 16.3%.
Oppenheimer Holdings Inc. (NYSE: OPY) today announced that its Board of Directors approved a share repurchase program that authorizes the Company to purchase up to 530,000 shares of the Company's Class A non-voting common stock, representing approximately 4.2% of its 12,636,523 currently issued and outstanding shares of Class A non-voting common stock. This authorization will supplement the 98,625 shares that remain authorized and available under the Company's previous share repurchase program covering up to 640,000 shares of the Company's Class A non-voting common stock, which was announced on July 26, 2019, for a total of 628,625 shares authorized and available for repurchase. The share repurchase program is expected to continue indefinitely.
TORONTO, June 13, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Easton Pharmaceuticals Inc. (OTC: EAPH) (“Easton” or “the Company”) announces it has filed its quarterly report for the three months ended March 31, 2019, and provides several key updates on its business initiatives. In the first quarter of 2019, Easton Pharmaceuticals recorded revenues of $612,689 and turned from a loss to post net income of $7,878. Revenues were generated from the Company’s contract with a prominent developer to frame 150 new homes in Whitby, Ontario, Canada, under its newly created real estate development division.